GSK 299423 explained

GSK 299423 or GlaxoSmithKline 299423 is an antibiotic chemical compound that has been identified as potentially effective in treating patients infected with bacteria expressing the New Delhi metallo-beta-lactamase. The antibiotic inhibits the enzyme topoisomerase, which bacteria need to replicate.^{[1] [2] [3]}

No animal studies have been reported. No application has been made for human clinical trials.

Notes and References

1. Sten Stovall, "Glaxo:New Compound Offers Way To Fight Drug-Resistant Bacteria," The Wall Street Journal, August 4, 2010
2. Melly Alazraki, "GlaxoSmithKline Finds Compound That Could Help Fight 'Superbugs' " Daily Finance, August 6, 2010
3. Nature . Type IIA topoisomerase inhibition by a new class of antibacterial agents . Bax BD, etal . 466 . 935–40 . 10.1038/nature09197 . 4 August 2010 . 20686482 . 7309. 2010Natur.466..935B . 205221405 . (primary source)